157 related articles for article (PubMed ID: 14679399)
21. Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.
Kim TH; Kim KA; Lim YS; Gwak GY; Yoon JH; Kang GH; Lee HS
Intervirology; 2005; 48(4):230-8. PubMed ID: 15920347
[TBL] [Abstract][Full Text] [Related]
22. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
[TBL] [Abstract][Full Text] [Related]
23. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
24. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
[TBL] [Abstract][Full Text] [Related]
25. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
[TBL] [Abstract][Full Text] [Related]
26. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
[TBL] [Abstract][Full Text] [Related]
30. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
Kohno H; Aimitsu S; Kitamoto M; Aisaka Y; Kawakami H; Chayama K
Intervirology; 2006; 49(6):362-9. PubMed ID: 16926549
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection.
MacQuillan GC; Mamotte C; Reed WD; Jeffrey GP; Allan JE
J Med Virol; 2003 Jun; 70(2):219-27. PubMed ID: 12696108
[TBL] [Abstract][Full Text] [Related]
32. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
Sezaki H; Suzuki F; Akuta N; Yatsuji H; Hosaka T; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Miyakawa Y; Kumada H
Intervirology; 2009; 52(1):43-8. PubMed ID: 19372703
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
[TBL] [Abstract][Full Text] [Related]
35. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
36. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.
Bekkering FC; Brouwer JT; Hansen BE; Schalm SW
J Hepatol; 2001 Mar; 34(3):435-40. PubMed ID: 11322206
[TBL] [Abstract][Full Text] [Related]
38. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
39. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
40. Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Omori-Mizuno Y; Nakayama N; Inao M; Funyu J; Asabe S; Tomita K; Nishikawa K; Hosoda Y; Tanaka M; Hashimoto Y; Yakabi K; Koshima Y; Mochida S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1384-90. PubMed ID: 25778685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]